Regeneron Stock: $636 Target From Benchmark

By Amit Chowdhry ● July 9, 2021
  • The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received a price target increase from $590 to $636. These are the details.

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received a price target increase from $590 to $636. And Benchmark analyst Aydin Huseynov assigned the company a “Buy” rating.

Benchmark analyst Aydin Huseynov believes that the recent rally in the stock is in anticipation of a series of REGEN-COV Emergency Use Authorizations. And the investors are responding to the assumed strong commercial performance of the company portfolio.

Plus Huseynov expects future official announcements from the company will also drive further strong stock performance.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.